205.70 USD
↘ 8.30 (3.88%)AT CLOSE (03:59 PM EDT)
Jazz Pharmaceuticals, Inc.
JAZZNASDAQ • USD
208.70
↗ 3.00 (1.46%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
208.70
↗ 3.00 (1.46%)
Market: CLOSED
JAZZ is currently priced at $205.64. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". This is driven by a bullish Golden Cross on the moving averages. Valuation metrics suggest JAZZ is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Oct 26, 2026.
Open?$215.29
High?$216.43
Low?$205.00
Prev. Close?$214.00
Volume?970.0K
Avg. Volume?806.2K
VWAP?$208.10
Rel. Volume?1.20x
Bid / Ask
Bid?$175.75 × 100
Ask?$230.90 × 100
Spread?$55.15
Midpoint?$203.33
Valuation & Ratios
Market Cap?13.9B
Shares Out?64.9M
Float?62.2M
Float %?95.8%
P/E Ratio?14.77
P/B Ratio?2.89
EPS?$14.49
Dividend?0.00%
Ex-Dividend?N/A
RelatedAXSM
News
Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Themes
Employees
2.9K
Market Cap
13.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2007-06-01
Address
FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?77
Z-Score?46
Momentum?69
Short Sent.?49
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.30Grey
Confidence?77%Moderate
Short InterestHigh
Short % of Float?9.43%Elevated
Short Interest?5.9M
Days to Cover?6.9
Free Float62.2M
Avg Daily Volume854.8K
Settlement Date2026-10-15
Financial Health
Current Ratio?1.78Adequate
Quick Ratio?1.58Adequate
Cash Ratio?0.73Adequate
Debt/Equity?0.91Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score89/100
P/E?14.8CHEAP▾
S&P81
P/B?2.89CHEAP▾
Peers100
S&P58
P/S?3.02FAIR▾
Peers100
S&P50
P/FCF?9.2CHEAP▾
S&P91
EV/EBITDA?10.3CHEAP▾
S&P79
EV/Sales?3.61FAIR▾
Peers100
S&P52
Returns & Efficiency
ROE?19.6%STRONG▾
S&P65
ROA?8.5%STRONG▾
S&P68
Cash Flow & Enterprise
FCF?$1.5B
Enterprise Value?$16.6B
Fundamentals ratios updated end of day